Milan

• This is a phase III randomised, double-blind, placebo-controlled, multicentre, global study to assess the effectiveness and safety of standa … Ended
  2022-502747-35-00 5 2019-02-18 Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
• A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Ended
  2023-508655-39-00 7 2019-02-13 Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia(CMML)
• Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended
  2023-508127-13-00 4 2019-01-25 Adult patients with refractory or relapsed follicular lymphoma
• A study of full treatment-free remission in patients with chronic myeloid leukemia Ended
  2024-516122-66-00 4 2019-01-18 Chronic myeloid leukemia
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended
  2022-502124-52-00 5 2018-12-18 Advanced epithelial ovarian cancer
• A study of Chemo only versus Chemo plus Nivo with or without BMS986205, Followed by Post- Surgery Therapy with Nivo or Nivo and BMS986205 in … Ended
  2024-512158-12-00 5 2018-12-14 Bladder Cancer Muscle-Invasive Bladder Cancer
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 4 2018-11-26 Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously tre
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimum … Ended
  2023-509061-20-00 9 2018-11-22 Advanced solid tumors
• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 5 2018-09-27 Moderately to Severely Active Crohn's Disease
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 4 2018-09-03 Mantle Cell Lymphoma
• A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended
  2023-509975-17-00 4 2018-04-12 Relapsed/Refractory Follicular Lymphoma
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe … Ended
  2023-504209-35-00 5 2018-04-04 Early-Stage Resectable Non-small cell lung cancer (NSCLC)
• A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat … Ended
  2024-510634-41-00 4 2018-02-22 Recurrent, metastatic, or persistent Cervical Carcinoma
• Gene therapy study using a frozen formulation of OTL-200 in patients with Metachromatic Leukodystrophy (MLD) Ended
  2024-511970-66-00 5 2017-12-13 Metachromatic Leukodystrophy (MLD)
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended
  2023-509595-42-00 5 2017-10-31 Gastric and gastroesophageal junction (GEJ) adenocarcinoma
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C … Ended
  2023-509167-24-00 4 2017-10-02 Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced
• A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended
  2023-508925-29-00 1 2017-06-29 Advanced solid tumors
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma

Showing 2,281–2,304 of 2,361 trials